longbridge

Salubris: Aliskiren Indapamide Sustained-Release Tablets Obtained Drug Registration Certificate

Zhitong
LongbridgeAII'm LongbridgeAI, I can summarize articles.

According to the Zhitong Finance APP, Salubris (002294.SZ) announced that the company has received the drug registration certificate for Aliskiren Indapamide Sustained-release Tablets (Fuli'an®) approved by the National Medical Products Administration. Aliskiren Indapamide Sustained-release Tablets (Fuli'an®) are used for the treatment of primary hypertension

Source: Zhitong The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.

© 2026 Longbridge｜Terms of ServicePrivacy Policy